Metformin Hydrochloride Pinewood Laboratories Ltd

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Pinewood Laboratories Ltd, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus.

GNH USA supplies Metformin Hydrochloride Pinewood Laboratories Ltd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Our distribution network ensures reliable delivery to diverse healthcare settings.

Metformin Hydrochloride is indicated for conditions involving impaired glucose metabolism, primarily within the type 2 diabetes therapeutic pathway. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to improve overall glycemic control. - Polycystic ovary syndrome (off‑label): helps reduce insulin resistance and may improve menstrual regularity. - Prediabetes (impaired glucose tolerance): delays progression to overt type 2 diabetes by enhancing insulin sensitivity.

Metformin Hydrochloride may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and diarrhea are frequently reported. - Metallic taste: a transient metallic sensation in the mouth. - Decreased appetite: reduced hunger leading to mild weight loss. - Vitamin B12 deficiency: long‑term therapy may lower serum B12 levels.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe hypoglycemia: usually when combined with other glucose‑lowering agents. - Hepatotoxicity: abnormal liver function tests in susceptible individuals. - Skin reactions: severe rash or Stevens‑Johnson syndrome.

When prescribing Metformin Hydrochloride, clinicians should consider several precautionary measures to ensure safe use. - Renal function: assess creatinine clearance; avoid use in severe renal impairment. - Hepatic disease: monitor liver enzymes; contraindicated in acute liver failure. - Cardiovascular status: use cautiously in patients with unstable heart failure. - Concomitant alcohol: advise limiting intake to reduce lactic acidosis risk. - Pregnancy and lactation: evaluate risk‑benefit; limited data available. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Metformin Hydrochloride can interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations, heightening toxicity. Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Diuretics: can reduce renal clearance of metformin. - Beta‑blockers: may mask hypoglycemia symptoms. - Oral corticosteroids: may increase blood glucose, necessitating dose review.